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The immune system exists in a delicate equilibrium between inflammatory responses
and tolerance. This unique feature allows the immune system to recognize and respond
to potential threats in a controlled but normally limited fashion thereby preventing a
destructive overreaction against healthy tissues. While the adaptive immune system was
the major research focus concerning activation vs. tolerance in the immune system more
recent findings suggest that cells of the innate immune system are important players in
the decision between effective immunity and induction of tolerance or immune inhibition.
Among immune cells of the innate immune system dendritic cells (DCs) have a special
function linking innate immune functions with the induction of adaptive immunity. DCs
are the primary professional antigen presenting cells (APCs) initiating adaptive immune
responses. They belong to the hematopoietic system and arise from CD34+ stem cells
in the bone marrow. Particularly in the murine system two major subgroups of DCs,
namely myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) can be distinguished. DCs
are important mediators of innate and adaptive immunity mostly due to their remarkable
capacity to present processed antigens via major histocompatibility complexes (MHC)
to T cells and B cells in secondary lymphoid organs. A large body of literature has
been accumulated during the last two decades describing which role DCs play during
activation of T cell responses but also during the establishment and maintenance of
central tolerance (Steinman et al., 2003). While the concept of peripheral tolerance has
been clearly established during the last years, the role of different sets of DCs and their
particular molecular mechanisms of immune deviation has not yet fully been appreciated.
In this review we summarize accumulating evidence about the role of regulatory DCs in
situations where the balance between tolerance and immunogenicity has been altered
leading to pathologic conditions such as chronic inflammation or malignancies.
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MAJOR FUNCTIONAL STATES OF DCs DURING
IMMUNE ACTIVATION
A major focus of research into DC biology was built on obser-
vations during immune activation. DCs are a heterogeneous cell
population that can acquire diverse maturation states and func-
tions. Intensive studies of DC development in mice lead to the
conception that DCs derive under homeostatic conditions from
hematopoietic CD34+ stem cells in the bone marrow and poten-
tially in the intestinal lamina propria (Bogunovic et al., 2009)
while monocyte-derived DCs have been described under inflam-
matory conditions (Cheong et al., 2010). Also, human CD14+
CD34+ PBMCs were described to give rise to DCs by the influ-
ence of platelet endothelial cell adhesion molecule-1 (Ferrero
et al., 1998). Myeloid precursor cells in the bone marrow give
rise to common DC precursor cells with the ability to prolif-
erate and relocate to bone marrow, spleen, and lymph nodes.
The major function of DCs has been attributed to the initiation
steps of immune activation leading to protection of the individual
against invading pathogens and the immune surveillance against
transformed cells.
At least two categories of DCs have been described for the
mammalian immune system (Banchereau et al., 2000). Myeloid
DCs (mDCs) also called conventional DCs have a strong capa-
bility to capture antigens which enables them to stimulate T
cells. These major antigen presenting and activating cells com-
prise a very heterogeneous group of cells expressing high levels of
MHC class II and integrin CD11c on their cell surface, but also
other adhesion molecules, like LFA-1 (CD11a), LFA-3 (CD58),
ICAM-1 (CD54), ICAM-2 (CD50), and ICAM-3 (CD102). The
costimulatory molecules CD80 and CD86 have been established
as hallmarks of DC maturation during an immune response
with CD86 being expressed at early stages of maturation, while
CD80 (and also CD83) become upregulated in mature DCs.
The Langerhans cells of the skin are one major representative
subgroup of the mDCs continuum. Murine mDCs are character-
ized by the expression of CD11b and CD11c and are generated
in vitro by stimulation of bone marrow progenitor cells while
in the human, DCs are often generated from peripheral blood
monocytes using GM-CSF and IL-4 (Sallusto and Lanzavecchia,
1994).
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A second group of DCs are plasmacytoid DCs (pDCs) that
are found in circulation and in peripheral lymphoid organs. In
comparison to other APC the capacity of pDCs to present anti-
gens is rather low since immature pDCs express only low levels
of MHC-II or other costimulatory molecules. Upon activation
they secrete large amounts of IFNα and IFNβ (Cella et al., 1999;
Siegal et al., 1999). Infection with RNA- andDNA-viruses induces
IFN-related immune responses in pDCs human and mice after
the recognition of viral genomes via pattern recognition recep-
tors (PRR) such as toll-like receptors (TLRs) 7 and 9 (Lund
et al., 2003; Di Domizio et al., 2009; Swiecki and Colonna, 2010).
Characterization via surface receptors revealed that pDCs do not
express markers commonly present on human mDCs such as
CD11c, but express instead the interleukin 3 receptor (CD123)
and exclusively the type II c-type lectin BDCA-2 (CD303) which
is involved in the presentation of antigens to T cells (Dzionek
et al., 2001). In contrast to human pDCsmurine pDCs are charac-
terized by the expression of CD11c, B220, Gr-1, CD45RA, Ly49Q,
BST2, and Siglec-H (Gehrie et al., 2011). It is assumed that these
cells play a major role in anti-viral immune responses since they
produce high amounts of IFNα after viral infection.
A third group named follicular DCs (fDCs) can be found in the
germinal centers of lymph nodes presenting antigens to B cells to
maintain immune memory. fDCs extracted out of human ton-
sils have been found to express the surface receptors CD21, CD23
CD35, and cell cycle markers DRC-1, Ki-M4 or DR53 (Kim et al.,
1994). Interestingly, in contrast to pDCs and mDCs fDCs share
some common antigens such as 3C8 with fibroblasts suggesting
that these cells share some molecular programs (Lindhout et al.,
1999; Lee and Choe, 2003; Vinuesa et al., 2010).
Immature DCs patrol via the blood systems throughout the
body and can invade peripheral tissues to take up antigens
from infected or dying cells via macropinocytosis, phagocyto-
sis, and endocytosis (Steinman et al., 1999). Migration of DCs
from peripheral tissues to lymph nodes also occurs under steady
state conditions in absence of infection and might contribute
to tolerance induction. Receptors of the C-type lectin family
like DEC205, DCIR or the mannose receptor (CD206) directly
capture antigens and direct them to antigen processing anti-
gen processing machinery in the endosomal compartment or
the cytosol (Villadangos and Schnorrer, 2007). The expression
of PRR including TLRs, NOD-like receptors and RIG-like heli-
cases by DCs enables these immune cells to recognize bacterial
(e.g., LPS) or viral (e.g., single-stranded RNA) compounds, so
called pathogen associated molecular patterns (PAMPs) (Janeway
and Medzhitov, 2002). More recently, it was shown that DCs
also recognize intracellular host factors released to the extracel-
lular space after cell damage, called damage associated molecular
patterns (DAMPs) like HMGB1 or S100A/B proteins. mDCs are
found to express TLR1, TRL2, TRL4, TLR5, and TLR8, while
pDCs express TLR-7 and TLR-9. After activation of the TLR-
signaling cascade via the adaptor molecules MYD88 and TRIF
pro-inflammatory transcription factors like NFκB and several
interferon regulating factors (IRFs) are activated and lead mat-
uration of DCs and to the expression of immune activating
mediators (Hemmi and Akira, 2005). A central contribution to
immune activation is the presentation of processed antigens via
major histocompatibility complexes (MHC) in presence of cos-
timulatory molecules on the cell surface of DCs to T cells and
B cells in secondary lymphoid organs. The transport of peptide-
loaded MHC molecules to the cell surface is accompanied by an
increased expression of costimulatory molecules like CD80 and
CD86. Other typical maturation marker on matured human and
mice DCs are elevated levels of HLA-DR, CD40, CD80, CD1a,
and CD54 (Reis e Sousa, 2006). The activation of signaling cas-
cades downstream of PRRs also induces DCmigration to afferent
lymph nodes to present antigens to T cells and B cells (Hemmi
and Akira, 2005) which is mediated by the chemokine and hom-
ing receptor CCR7 along a gradient of the two chemokines
CCL19 Epstein-Barr virus-induced molecule-1 ligand chemokine
(ELC), and CCL21 Secondary lymphoid tissue chemokine (SLC)
(Sanchez-Sanchez et al., 2004; Riol-Blanco et al., 2005). Mature
mDCs secrete high amounts of inflammatory cytokines such as
IL-12, necessary for the differentiation of naïve T cells toward cer-
tain T helper cell subsets (Figure 1). In principle, DCs unite at
least four different signals in the immune synapse. One activation
signal is established by the presentation of processed antigens via
MHC molecules that interact with the T cell receptor complex.
The binding of the adhesion molecule ICAM-1 with LFA-1 on the
T cell surface strengthens the contact of both immune cells and
the so-called signal two is established by the interaction between
costimulatory molecules CD80/CD86 expressed on matured DCs
with CD28 on T cells. Finally, an interaction between CD40 on
DCs and CD40L on T cells is established leading to increased IL-
12 production of DCs. The elevated levels of IL-12 finally lead
to a TH1 polarization and secretion of the cytokine IFNγ which
is necessary for the recruitment of macrophages and cytotoxic T
cells. While there is no doubt about the exceptional role of DCs
during immune activation, more and more evidence has been
accumulated demonstrating that these specialized cells can also
exert regulatory functions.
DEFINING REGULATORY DENDRITIC CELLS
While activation and maturation of dendritic cells (DCs) and
their immunostimulatory capacity are clearly linked to a distinct
phenotypic change with upregulation ofMHCmolecules, costim-
ulatory molecules, and the enhanced production of inflammatory
cytokines, this is less clear for DCs exerting regulatory func-
tions. Initially, regulatory, inhibitory or even tolerance-inducing
capabilities were assigned to immature DCs, a differentiation
state prior maturation. It has been a common view that DCs
exist in an immature and a mature state. Initial experiments
demonstrated that immature DCs can induce tolerance, which
was explained by the finding that immature DCs process and
present antigens in the absence of costimulation, leading to
T cell anergy and deletion (Jonuleit et al., 2000; Lutz et al.,
2000; Reis e Sousa, 2006; Manicassamy and Pulendran, 2011).
However, during the last years, fully matured DCs with regula-
tory functions have been observed in numerous distinct settings
suggesting that regulatory DCs (DCreg) are a functional state
rather than a unique subpopulation defined by phenotypical
markers. For example, in a murine colitis model CD103+ DCs
acquire immune-activating functions under inflammatory con-
ditions and express pro-inflammatory cytokines (Laffont et al.,
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FIGURE 1 | Stimulatory and regulatory dendritic cells in health and
disease. DCs are a plastic lineage able to process and integrate signals from
the microenvironment. Under pro-inflammatory conditions stimulatory DCs
promote an effective immune response by stimulating T cell proliferation and
shaping T cell responses toward TH 1, TH 2, or TH17 phenotypes. This crucial
role allows the immune system to clear pathogens and keep transformed
cells in check. Nevertheless, uncontrolled DC activation can lead to tolerance
ablation, fostering the development of autoimmune diseases like rheumatoid
arthritis. Under a tolerogenic environment DCs acquire regulatory functions
suppressing T cell activation and proliferation and providing signals that
enable Treg and Tr1 differentiation and expansion. This function maintains
tolerance in organs like the gut which are exposed to a variety of harmless
antigens. However, DCreg function can be exploited by tumors and
pathogens leading to tumor progression and chronic infection.
2010). However, under steady state conditions CD103+ DCs in
the gut where shown to be strong inducers of T cell tolerance,
which was manifested by their capacity to induce Foxp3+ Treg
from CD4+ naïve precursors (Del Rio et al., 2010; Scott et al.,
2011). A similar situation was observed in the liver where low
numbers of pDCs are associated with viral persistence during
chronic hepatitis C infection while elevated numbers of highly
active DCs are associated with pathogen clearance (Lai et al.,
2007). At the same time resident pDCs in the liver promote
immune regulation through various mechanisms (Matta et al.,
2012). Yet another example is the coexistence of DCs with stimu-
latory and regulatory functions in the tumor microenvironment.
Depending on the expression of immunomodulatory factors and
cytokines in the tumor, DCreg together with other immunoregu-
latory cells can be recruited to the tumor environment (Shurin
et al., 2011; Gabrilovich et al., 2012). Further evidence for the
existence of fully matured DCreg came from a murine asthma
model, demonstrating that fully matured DCs expressing high
levels of costimulatory molecules stimulated Treg development via
an IL-10 depending mechanism (Akbari et al., 2001). In humans,
monocyte-derived DC stimulated with prostaglandin E2 (PGE2)
and TNFα exhibit a fully mature phenotype characterized by high
expression of costimulatory molecules and pro-inflammatory
cytokines, yet they suppress T cell activation via a combination
of factors like indoleamine 2,3 deoxygenase (IDO) and IL-10
(Popov et al., 2006, 2008; Von Bergwelt-Baildon et al., 2006).
Furthermore, it was shown that DCs with intermediate features
between the immature and mature state expressing costimulatory
molecules but only low levels of inflammatory cytokines, such
as IL-12, IL-6, and TNFα, are also characterized by regulatory
function (Lutz and Schuler, 2002). Moreover, the potential ther-
apeutical application of semi-mature DCs as tolerance promoters
have been recently reviewed (Lutz, 2012).
In summary, there seems to be significant heterogeneity of DC
populations with regulatory function, which might be due to the
plasticity of DCs capable of reacting to and integrating environ-
mental signals from different microenvironments. Nevertheless
they share the ability (1) to regulate or inhibit T cell activation,
and (2) to induce and promote Treg development and expansion
(Figure 1).
ANTI-INFLAMMATORY MEDIATORS CAN DRIVE DCs
TOWARD REGULATORY FUNCTION
Since regulatory function of DCs is linked to environmental cues
several soluble factors such as TGFβ, IL-10, or PGE2 known
to play a role in immune inhibition have been linked to the
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induction of regulatory DCs (Popov and Schultze, 2008). Even
under steady state conditions, these factors play an important
role for the integrity of many organ systems, particularly those
with close contact to the outside world such as lung or intes-
tine. For example the intestine is in constant contact with a
large variety of antigens and it is of vital importance to discrimi-
nate between harmless nutrients, commensal flora, and potential
threats (Iweala and Nagler, 2006). TGFβ is produced by intesti-
nal epithelial cells thereby fostering the generation of DCreg and
subsequently Treg cells. Neutralization of TGFβ directly leads to
a diminished DCreg capacity to induce Treg cells (Iliev et al.,
2009). Along the same lines, Belladonna and coworkers demon-
strated that CD8+ pDC rely on autocrine TGFβ stimulation
but also IDO to keep tolerance under steady state conditions.
Moreover, they showed that CD8− immunogenic DCs do not
produce TGFβ and yet externally added TGFβ induces IDO
changing immunogenic DC into DCreg (Belladonna et al., 2008).
TGFβ also plays an important role for immunosuppression in
the brain, which at least in part is also due to regulatory func-
tions of DCs in this compartment. In a recent report, it could be
demonstrated that blockade of TGFβ receptor signaling in DCs
caused severe autoimmune encephalitis indicating an important
role of this factor in DCs to maintain tolerance (Laouar et al.,
2008). Another well-established factor inducing immunoregula-
tory functions in DCs is interleukin-10 (IL-10). DCs exposed
to IL-10 fail to induce immunostimulatory cytokines such as
IL-12 (De Smedt et al., 1997) or TNFα. Moreover, IL-10 pre-
vents the upregulation of immunostimulatory molecules such as
MHC class II and CD86. The quintessence is an impaired abil-
ity of IL-10 primed DCs to induce allogeneic T cell responses
(Jonuleit et al., 2000; Moore et al., 2001; Pletinckx et al., 2011).
Since the functional outcome of DCs depends on the exogenous
signals integrated by these cells, it is not surprising that some
factors can have both immunostimulatory as well as regulatory
functions, depending on signal strength, time of exposure, and
combination with other factors. The effect of PGE2 exemplifies
such complex interaction. During acute inflammatory immune
responses PGE2 is widely expressed by epithelial cells, fibrob-
lasts, and immune cells infiltrating the inflamed site (Kalinski,
2012). In such situations PGE2 can serve as an enhancer of the
immunostimulatory response. PGE2 also increases CCR7 expres-
sion and is essential to promote DC migration toward the lymph
node-derived chemokines CCL19 and CCL21 (Scandella et al.,
2002; Legler et al., 2006). However, more recently it has been
reported that the PGE2 effect on CCR7 expression is only tran-
sient and that these PGE2-treated DCs secret reduced levels of
CCL19, the key chemokine attracting naïve and central memory
T cells (Muthuswamy et al., 2010). During extended inflamma-
tory responses and in chronic inflammation, PGE2 might deviate
DCs from a stimulatory into a regulatory phenotype. Under
such conditions, PGE2 can induce regulatory mediators such
as IL-10 (Kalinski et al., 1997) or thrombospondin-1 (Doyen
et al., 2003). We have previously shown that TNFα signaling
in presence of PGE2 induces regulatory DCs expressing a myr-
iad of inhibitory molecules such as IDO, IL-10, soluble CD25
or COX-2 further increasing PGE2 production (Von Bergwelt-
Baildon et al., 2006; Driesen et al., 2008; Popov et al., 2008).
Finally exposure of DCs to PGE2 leads to increased IL-12p40
secretion which is not accompanied by production of IL-12p35
leading to an overall diminished production of the bioactive IL-
12 heterodimer (Kalinski et al., 2001; Von Bergwelt-Baildon et al.,
2006).
As exemplified for TGFβ, IL10 or PGE2, DCs can integrate
signals from their microenvironment in a fashion that induces
regulatory rather than immunostimulatory activity by these cells.
Under steady state conditions such signal integration is critical for
organ homeostasis. Any changes in the balance between regula-
tory and immunostimulatory signals can lead to tissue pathology.
While decreased regulatory capacity of DCs can be associated
with enhanced inflammatory responses associated with tissue
destruction, increases in DCreg are linked to chronic inflamma-
tion and malignant diseases.
REGULATORY DCs IN CANCER
Although there is clear evidence that the immune system can
eliminate malignant cells the generation of a clinically effi-
cient immune response against cancer is a challenging task
(Schreiber et al., 2011). Over the last 15 years, therapies based
on the immunostimulatory capacities of DCs have been a
major focus of tumor immunotherapy, yet, most clinical stud-
ies have not resulted in meaningful clinical responses (Palucka
and Banchereau, 2012). A major hurdle for DC-based tumor
immunotherapy is to overcome regulatory circuits within the
tumor microenvironment. In addition to many other cell types
with regulatory or suppressive function such as myeloid derived
suppressor cells (Palucka and Banchereau, 2012), Treg cells or
deviated macrophages, DCs also seem to be altered in vari-
ous ways in malignancies (Table 1). In some cancer types DCs
are depleted from the tumor site itself but also from the cir-
culation suggesting that these malignancies induce significant
changes in DC generation (Almand et al., 2000; Gabrilovich,
2004; Satthaporn et al., 2004; Tjomsland et al., 2010). In other
cancer types, DC maturation was shown to be impaired and this
feature was associated with lack of T cell activation and the induc-
tion of T cell anergy thereby inducing tolerance against the tumor
(Ma et al., 2012; Shurin et al., 2012). In such situations, DC mat-
uration might not simply be blocked, but more likely DCs are
deviated toward a regulatory function by integrating signals from
the tumor microenvironment (Gabrilovich et al., 2012). Such
tumor-associated DCreg are not only able to suppress effector T
cells but also induce the recruitment and expansion of Treg cells.
FUNCTIONAL IMPAIRMENT OF DCs LEADS TO DEFECTIVE
T CELL PROLIFERATION AND TOLERANCE
At the same time when numerous clinical trials were already con-
ducted to test the efficacy of DCs as cellular cancer vaccines it
was revealed in human tumor biopsies as well as murine and
rat tumor models that DCs in many malignancies present an
impaired function, manifested in poor antigen processing and
presentation, impaired migration and low presence of costimu-
latory molecules (Gabrilovich, 2004; Yang and Carbone, 2004).
Early studies revealed that tumor infiltrating DCs present poor
capabilities to induce T cell proliferation in an allogeneic mixed
lymphocyte reaction in vitro (Troy et al., 1998). Consistent with
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Table 1 | Regulatory dendritic cells in immune diseases.
Disease DC phenotype Surface marker Secreted immune
modulators
Literature Function
Cancer Impaired
maturation/immature
Downregulation of
MHCII, CD80, CD83,
CD86
Missing IL-12 Aalamian et al., 2001;
Gabrilovich, 2004; Yang
and Carbone, 2004;
Bharadwaj et al., 2007;
Michielsen et al., 2011;
Ma et al., 2012; Shurin
et al., 2012
Induction of: T cell
anergy;
T cell apoptosis
Regulatory CD25, PD-1, B7-H1 IL-10, TGFβ, Kynurerine,
sCD25
IDO, COX-2, ARG1
Toossi et al., 1990;
Williams et al., 1999;
Benoit et al., 2004;
Rodriguez et al., 2004;
Ghiringhelli et al., 2005;
Chemnitz et al., 2006;
Von Bergwelt-Baildon
et al., 2006; Chung et al.,
2009; Dumitriu et al.,
2009; Krempski et al.,
2011; Gabrilovich et al.,
2012; Scarlett et al., 2012
CHRONIC INFLAMMATION
Systemic lupus
erythematosus
pDCs HLA-DR, CD4 (CD11c
reduced)
IFNα, IL-10 Blanco et al., 2001; Lee
et al., 2008; Yan et al.,
2008; Jin et al., 2010
Suppression of:
T cell activation;
T cell proliferation;
T cell function
Rheumatoide arthritis Regulatory CD11b, CD11c, CD18 TGFβ, BAFF, IDO Morelli et al., 2003;
Zhang et al., 2005;
Kavousanaki et al., 2010
Obesity FFA-
dependent/Regulatory
(USFAs)
IL10R;
Downregulation of
MHCII, CD80, CD83,
CD86
IL-10 (missing IL-12
secretion)
Aliberti et al., 2002;
Loscher et al., 2005;
Miyake et al., 2010;
Draper et al., 2011
CHRONIC INFECTION
Viral infection Impaired
maturation/function
(Virus-dependent)
Downregulation of
CD1a, CD1b,
DC-SIGN, CD80,
CD83, CD86
IFNα, IL-10, IL-1β
(missing IL-12, IL-6,
TNFα secretion)
Kruse et al., 2000;
Sarobe et al., 2003;
Smed-Sorensen et al.,
2004; Martinson et al.,
2007; Tilton et al., 2008;
Harman et al., 2011;
Chentoufi et al., 2012;
Dental et al., 2012; Tu
et al., 2012
Parasitical infection Regulatory CD11c, CD25 TNFα, IFNγ, IL-10, TGFβ,
COX2, IDO, S100
Von Bergwelt-Baildon
et al., 2006; Poncini
et al., 2008; Popov et al.,
2008; Li et al., 2011
these findings DCs differentiated from monocytes in presence of
conditioned media derived from prostate or pancreatic cancer
cell lines, showed low levels of HLA-DR, costimulatory molecules
CD40, CD80, CD86, and the DC maturation marker CD83
(Aalamian et al., 2001; Bharadwaj et al., 2007). Moreover, DCs
cultured in presence of human colorectal cancer explants failed
to upregulate CD86 and CD80 expression in response to LPS
(Michielsen et al., 2011). Other examples for immune deviation
of DCs in cancer came from rat cancer models demonstrating the
presence of DCs expressing low levels of costimulatory molecules
that were incapable of inducing T cell activation (Chaux et al.,
1997; Bonnotte et al., 2004). These and many other reports sug-
gested that the lack of immunostimulatory function of DCs in
context of malignant disease was mainly due to lack of the nec-
essary stimulatory molecules (MHC, CD80, and CD86) which
might be explained by a strong influence of this field of research
by findings in T cell immunology at the same time suggest-
ing that presence or absence of costimulation on APC is mainly
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responsible for decision making between T cell immunity or
tolerance. However, with the identification of regulatory cells
such as Treg cells and the appreciation of the complexity of
immunoinhibitory signals within the tumor microenvironment,
this rather simple model of lack of immune function by DCs
has been gradually dismissed. In fact, it is now well appreciated
that DCs in cancer can acquire a spectrum of different functional
states ranging from strongly immunostimulatory to regulatory or
even suppressive and inhibitory states inducing T cell tolerance
or even deletion. Some of the molecular mechanisms respon-
sible for regulatory rather than immunostimulatory functions
of DCs in tumor microenvironments are described in the next
section.
DCs EXPOSED TO THE TUMORMICROENVIRONMENT
ACQUIRE A REGULATORY FUNCTION
The tumor microenvironment provides many inhibitory signals
that can be sensed by DCs leading to a change in their functional
state. Soluble factors, such as IL-10, TGFβ, and PGE2 (Popov and
Schultze, 2008) secreted by the tumor have been clearly linked
to the induction of DCreg (Table 1). Furthermore, Scarllet and
coworkers showed in a murine model of ovarian cancer that the
switch from immunostimulatory to immunoregulatory function
of mDCs at the tumor site determined the onset of aggressive
malignant tumors that escaped immune surveillance (Scarlett
et al., 2012). This data suggested that the interaction of DCs
within the tumor microenvironment might be relevant in the
control of disease progression—at least in ovarian cancer.
Among other factors, the enzymes IDO and arginase-1 as
well as TGFβ have clearly been linked to the generation and
enrichment of DCreg in the tumor microenvironment. IDO cat-
alyzes the first rate-limiting step in tryptophan (Trp) degradation
(Yamamoto and Hayaishi, 1967). Its activity has a dual effect
leading to Trp depletion and accumulation of Trp catabolites,
collectively known as kynurenines (Sugimoto et al., 2006). IDO
expression has been detected in biopsies of patients with differ-
ent malignancies such as esophageal (Von Bergwelt-Baildon et al.,
2006), squamous cell carcinoma (McGee-Lawrence et al., 2011),
non-small cell lung carcinoma (Sim et al., 2012), and melanoma
amongst others (Munn and Mellor, 2007). IDO activity was
linked to multiple mechanisms in immune tolerance in vitro as
well as in vivo. Trp starvation and accumulation of Trp catabo-
lites lead to T cell proliferation arrest and apoptosis (Terness
et al., 2002; Von Bergwelt-Baildon et al., 2006). Furthermore,
DCs can induce the expansion of autologous Treg via an IDO-
dependent mechanism (Chung et al., 2009). More recently, it has
been reported inmice that the Trp catabolite kynurenine can bind
and activate the aryl hydrocarbon receptor (AHR) on T cells lead-
ing to AHR-dependent Treg generation (Mezrich et al., 2010).
The induction of active allograft-specific tolerance by AHR acti-
vation has been described earlier in Balb/c mice (Hauben et al.,
2008). In this study DC out of VAG539-tolerized mice induced
the development of CD25+Foxp3+ T cells.
Our group has shown that mDCs cultured in the presence
of TNFα and PGE2, two factors with high abundance in the
microenvironment of many tumors (Williams et al., 1999; Benoit
et al., 2004; Chemnitz et al., 2006), upregulated IDO expression
concomitant with an increased expression of IL-10, COX-2, and
the interleukin 2 receptor alpha chain (CD25) (Popov et al.,
2006, 2008; Von Bergwelt-Baildon et al., 2006; Driesen et al.,
2008). Soluble CD25 has been associated with poor prognosis
in solid and hematological malignancies (Paietta et al., 1997) All
these immunoregulatory mechanisms together equip DCreg with
powerful mechanisms to restrain T cell responses. IDO+DCreg
can mediate apoptosis of effector T cells and at the same time
promote Treg cell expansion thereby shifting the balance fur-
ther toward immune inhibition or suppression (Fallarino et al.,
2002). Furthermore, we demonstrated that cell surface expression
of CD25 and secretion of soluble CD25 act as decoy receptors
for IL-2 (Toossi et al., 1990; Von Bergwelt-Baildon et al., 2006)
which further inhibits T cell function. Since, IDO+CD25+ DCreg
are present in the tumor microenvironment one could postu-
late that these regulatory cells—similar to other myeloid cells
with inhibitory functions are part of the immune deviation from
activation to inhibition in the tumor microenvironment. In this
context, a rather alerting observation was made during a clini-
cal vaccine trial. Patients treated with mDC based cancer vaccines
showed a recruitment of IDO+ immune cells together with Treg
cells to the site of injection suggesting that under some circum-
stances such cellular therapies might actually enhance regulatory
functions of DCs rather than potentiating immune activation
(Wobser et al., 2007).
In addition to IDO+ mDCs, the accumulation of pDCs in
tumors and tumor lymph nodes is also well documented for
different malignancies including melanoma (Vermi et al., 2003)
or head and neck cancer (Hartmann et al., 2003). Moreover,
IDO+ pDCs present in murine and human tumor-draining
lymph nodes, were reported to induce T cell anergy toward spe-
cific tumor antigens. Importantly, the interaction of CD80/CD86
receptors on IDO+ pDCs with CTLA-4 on Treg cells was an
important molecular interaction leading to Treg cell expan-
sion and subsequently antigen-specific anergy in effector T cells
(Baban et al., 2005). More recently, Watkins and coworkers
reported the presence of IDO+ pDCs in human and murine
prostate cancer. These IDO+ DCs suppressed T cell proliferation
and induced T cell tolerance. By gene expression profiling the
authors defined a regulatory gene signature of these IDO+ pDCs,
which was controlled by the transcription factor FOXO3 (Watkins
et al., 2011).
Another enzyme that has been implicated as an immunoreg-
ulatory molecule in myeloid cells including DCs in the tumor
context is arginase-1 (ARG1). ARG1 catalyzes arginine conver-
sion into urea and L-ornithine, causing the depletion of the
non-essential amino acid arginine (Munder, 2009). High ARG1
activity has been described in patients with various malignan-
cies including gastric, colon, breast, and lung cancers (Rodriguez
et al., 2004). In murine models it was reported that mDC upregu-
late ARG1 when exposed to different cancer cell lines. Moreover,
ARG1+ mDC suppressed T cell proliferation via arginine deple-
tion (Liu et al., 2009; Norian et al., 2009). In T cells L-arginine
deprivation leads to an arrest of the cell cycle during G0-G1 tran-
sition (Rodriguez et al., 2007) and to reduced expression of the
TCR ζ-chain (Rodriguez et al., 2004). These findings suggest that
upregulation of ARG1 is yet another mechanism of DCreg that
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impacts on the outcome of T cell activation, at least in the murine
model. However, the relevance of these findings in human tumors
has not yet been clarified.
A major immunosuppressive factor within the tumor
microenvironment is TGFβ (Li and Flavell, 2008). It has been
well documented that mDCs upregulate TGFβ expression and
secrete TGFβ once exposed to tumor cell lines, e.g., non-small
cell lung carcinoma cell lines (Dumitriu et al., 2009). Moreover,
interaction of T cells with TGFβ producing mDCs leads to the
induction of CD4+CD25+Foxp3high T cells (Dumitriu et al.,
2009). Consistent with these findings Ghiringhelli and cowork-
ers showed in mouse and rat colon cancer models that DCs
exposed to tumor cells could acquire the capacity to secrete
TGFβ and to stimulate naturally occurring Treg cells in vivo
(Ghiringhelli et al., 2005). Therefore, expression of TGFβ is
yet another mechanisms by which DCs exert regulatory rather
than immunostimulatory function in the tumor microenviron-
ment. More recently, the expression of inhibitory cell surface
molecules PD-1 and B7-H1 on a subset of DCs in a murine
model of ovarian cancer was linked to suppression of T cell
proliferation and this effect could be abolished by blocking anti-
PD-1 antibodies (Krempski et al., 2011). These data suggest
that PD-1 and B7-H1 expression on DC can also contribute to
immunoregulation or suppression by DCs in the tumor microen-
vironment. Altogether, there is accumulating evidence that the
absence of T cell immunity in cancer is not solely due to the
lack of expression of MHC and costimulatory molecules on DCs.
Rather the existence of multiple inhibitory pathways and effec-
tor molecules in tumor-associated DCs are major mechanisms
of immune deviation in cancer and DCs showing such hall-
marks are part of a larger family of regulatory DCs. Further
studies are necessary to delineate whether a hierarchy of regula-
tory pathways exists or whether these mechanisms are co-existing.
This will be particularly important when developing novel strate-
gies to overcome immunoregulation in the tumor microen-
vironment as a basis for the development of effective cancer
immunotherapy.
DENDRITIC CELLS IN CHRONIC INFLAMMATION
Chronic inflammation results from prolonged inflammatory
immune responses that are not terminated despite the fact
that the causing stimuli are often eliminated. Stimuli induc-
ing chronic inflammatory responses vary widely ranging from
numerous pathogens, self-antigens to chemical compounds.
Chronic inflammatory responses are associated with diseases
such as diabetes, atherosclerosis, or obesity. Another deviation
from a normal immune response occurs in many autoimmune
diseases and chronic exposure to allergens. Allergic responses
can turn into prolonged inflammatory responses with signifi-
cant changes of the inflammatory response during later time
points which is similarly observed in many autoimmune diseases.
In such situations, resident immune cells become continuously
activated and recruit further immune cells which invade the
inflamed tissue further fueling the inflammatory response. Albeit
pro-inflammatory cytokines, NO, arachidonic acid metabolites
and ROS are major compounds under such conditions, mech-
anisms exist that change the cellular programs of immune cells
from immunostimulatory programs resolving inflammation to
chronic inflammatory programs supporting chronification of the
response. Again, myeloid cells including both macrophages and
DCs play an essential role in deregulating inflammatory responses
into chronic inflammation.
REGULATORYMECHANISMS IN DCs SEEM TO BE DEFECTIVE IN
SYSTEMIC LUPUS ERYTHEMATOSUS
While regulatory or suppressive myeloid cells seem to play a cen-
tral role for immune deviation in cancer, regulatory functions of
these cells seem to be reduced or even lacking in autoimmune
diseases such as systemic lupus erythematodes (SLE), rheuma-
toid arthritis, or psoriasis (Table 1). SLE is an autoimmune dis-
ease characterized by the loss of tolerance against self-antigens.
Furthermore, an imbalance of TH1 and TH2 cells in favor of TH2
responses has been reported to be accommodated by decreased
expression of IL-18 with unchanged expression levels of IL-10
in pDCs of SLE patients (Jin et al., 2010). Despite this dysbal-
ance in pDCs that might favor immunoregulation when using
pDCs of SLE patients in allogeneic MLR assays they failed to
induce the expansion of Foxp3 expressing CD4+CD25+ Treg
cells (Jin et al., 2010). These data follow along the lines that
activated DCs in this autoimmune disease might be incapable
of suppressing effector T cell activation thereby contributing
to the persistence of inflammation. Despite the lack of DCs to
induce Treg cells, Foxp3+CD4+CD25+ T cells have been reported
to be elevated in peripheral blood of SLE patients, however
their suppressive function seemed to be impaired which was
related to high levels of IFNα secreted by antigen presenting
cells (APCs) of SLE patients (Yan et al., 2008). In SLE patients
pDCs seem to be a main source for IFNα. It is assumed that
immune complexes containing DNA or RNA act as inflam-
matory stimuli maintaining the IFNα production in pDCs via
TLR7 and TLR9 (Means et al., 2005; Savarese et al., 2006).
However, other immune cells might also contribute to the inter-
feron storm. For example, monocytes cultured in the presence of
IFNα-rich sera from SLE patients differentiated into IFNα pro-
ducing DCs (Blanco et al., 2001; Ueno et al., 2007) suggesting
that a feed-forward loop exists that supports chronification of
the autoimmune response in SLE. In a murine model of SLE
chronification of the immune response inducing IFNα produc-
tion in immature Ly6Chigh monocytes can also be initiated by
treatment with tetramehtylpentadecane (Lee et al., 2008) further
supporting the hypothesis that the lack of induction of DCs with
regulatory function is a major mechanisms of prolongation of
exacerbated autoimmune responses in SLE patients. As a logical
consequence novel therapeutic concepts for SLE are targeting at
the point of induction of regulatory DCs. For example, Zhang
and coworkers recently described that treatment with immune
complexes lead to elevated levels of PGE2 secretion by FcγRIIb-
overexpressing DCs which correlated with an elevated capacity to
suppress T cell activation (Zhang et al., 2011). Clinically, injec-
tion of immune complex-treated FcγRIIb-overexpressing DCs
into lupus-prone MRL/lpr mice was associated with prolonged
survival of these mice. In another mouse model the nucleosomal
histone peptide epitope H4(71-94) was used in subnanomo-
lar doses to induce DCreg which expressed TGFβ but showed
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reduced levels of IL-6 supporting the generation of Treg cells
and suppression of pro-inflammatory TH17 cells (Kang et al.,
2007). One other therapeutical approach targeted the central
pro-inflammatory transcription factor NFκB. Inhibition of this
transcription factor in a murine SLE model in FcγRIIb-deficient
mice with andrographolide or the anti-diabetic drug rosiglitazone
lead to induction of DCreg (Kalergis et al., 2009). The diureticum
triamterene is another compound which might be useful for the
therapy of SLE because it is able to induce IDO activity in mDCs
and such IDO+ DCs have been described to induce fully func-
tional Foxp3 positive CD4+CD25+ T cells (Ghosh and Branch,
1975; Chung et al., 2009).
LACK OF REGULATORY DC FUNCTION IS ASSOCIATEDWITH JOINT
INFLAMMATION IN RHEUMATOID ARTHRITIS AND PSORIASIS
As revealed in murine model systems, DCs play an essential
role in keeping immune homeostasis in the joint. Under these
conditions, joint derived self-antigens from apoptotic cells can
be recognized by DCs via the heterodimeric receptors CR3
(CD11c/CD18) and CR4 (CD11b/CD18) belonging to the β2-
integrin family of adhesion molecules (Morelli et al., 2003).
Activation of DCs by these receptors induces a regulatory DC
phenotype associated with suppressed IL-12 production and
elevated secretion of TGFβ. Moreover, it was shown that such
DCs are capable of inducing T cell anergy (Morelli et al.,
2003).
Rheumatoid arthritis (RA) is a chronic autoimmune disease
associated with production of elevated levels of pro-inflammatory
cytokines, including IL-12, IL-6, IL-1, IL-23, and TNFα, that are
involved in activation of naïve T cells and directing their polar-
ization into TH1 and TH17 cells. DCs are implicated as major
players for the development and persistence of inflammation but
also the resulting joint and bone destruction (Table 1). Albeit
the number of CD303+ pDCs and CD1c+ mDCs is significantly
reduced (Kavousanaki et al., 2010) in patients with active RA,
DCs invading synovial fluids are quickly activated in response to
joint-associated factors such as cartilage glycoprotein 39 but also
pro-inflammatory stimuli including cytokines and chemokines
and other proteins derived from dying cells within synovial fluids
(Van Bilsen et al., 2004). DCs in RA patients are also involved in
elevated B cell activation followed by proliferation and antibody
production. As shown in a murine collagen-induced arthritis
model B cell activation seems to be mainly related to the secre-
tion of the cytokine BAFF (B-cell activating factor) which belongs
to the TNF family (Zhang et al., 2005). A switch from regula-
tory to inflammatory functions of DCs together with an overall
reduced number of DCreg in RA patients suggests that a repro-
graming of DCs back to a regulatory phenotype might be an
appealing therapeutic strategy for these patients. In fact, higher
numbers of pDCs expressing IDOwere found in peripheral blood
of RA patients following current therapy regimens. These DCreg
were reported to convert naïve T cells into IL-10 secreting Treg
cells (Kavousanaki et al., 2010). Therefore, a more specific ther-
apeutic attempt in comparison to currently used global immune
suppressive drugs, like methotrexate and infliximab, might be to
revert back highly activated DCs showing a pro-inflammatory
profile into DCreg capable of suppressing autoreactive T cells.
Indeed, several early ex vivo vaccination trials, like for exam-
ple the phase I clinical trial Rheumavax at the University of
Queensland (Australia) or AutoDECRA at Newcastle University
(UK) aim to reestablish T cell tolerance by induction of Treg cells
via modification of DC function. Another approach might be
to disrupt costimulatory interactions between DCs and T cells.
Cytotoxic T lymphocyte antigen-4 (CTLA4) fused to IgG1 inter-
rupts the costimulatory B7/CD28 interaction between T cells and
DCs preventing the activation and proliferation of T effector cells
(Dall’Era and Davis, 2004). Furthermore, the binding of CTLA4
or its IgG1 fusion molecule was found to induce IDO expres-
sion in DC after binding to the B7 surface receptor (Grohmann
et al., 2002). Adoptive transfer of CTLA4-Ig treated CD11c+
DCs into collagen-induced arthritic mice induced the expansion
of CD4+CD25+Foxp3+ Treg cells and prevented the onset of
arthritis efficiently (Ko et al., 2010). Another approach to target
costimulation was recently achieved by siRNA (short interfering
RNAs) technology. DCs loaded with the arthritogenic Ag collagen
II and treated with siRNAs targeting the costimulatory molecules
CD40, CD80, and CD86 were used in an arthritis mouse model.
Treatment with these re-programmed DCs resulted in downreg-
ulation of IL-2, IFNγ, TNFα, and IL-17, which in turn resulted in
elevated levels of Foxp3+ Treg cells (Zheng et al., 2010). Another
approach to induce DCreg was recently published demonstrating
that dual lentiviral transfer of a constitutiveMEK-1mutant with a
fusion protein containing invariant chain ofMHC and ovalbumin
(IiOVA) leads to activation of ERK signaling thereby inducing
TGFβ production by DCs (Arce et al., 2011). As a consequence
ERK-activated DCs induced the expansion of Foxp3+ Treg cells
which prevented joint destruction.
Another example for the lack of DC regulatory function in
autoimmunity is psoriasis, one of the most common inflamma-
tory diseases, which is characterized by dermatosis with hyper-
proliferation of keratinocytes. In this autoimmune disease autore-
active, constitutively activated T cells secrete cytokines which
support the proliferation of dermal cells. Genetic, environmen-
tal and immunological factors define the severity of psoriasis,
but the cause of the disease is still unknown. Psoriasis is also
characterized by a reduced number of circulating pDCs while
at the same time increased numbers of pDCs are recruited
to psoriatic lesions and healthy skin (Skrzeczynska-Moncznik
et al., 2009). IFNα itself, but also other soluble mediators like
chemerin have been suggested to be responsible for this reloca-
tion of pDCs in psoriasis (Skrzeczynska-Moncznik et al., 2009).
In the early phase of psoriasis pDCs themselves secrete IFNα
subsequently inducing the activation and expansion of T cells
(Nestle et al., 2005). Elevated expression of IFNα by DCs in
psoriasis might be related to the identification of high level
expression of the endogenous anti-microbial peptide LL37 in pso-
riatic lesions. LL37 can bind to self-DNA resulting in complex
structures that activate pDCs via the pattern recognition recep-
tor TLR9 thereby inducing IFNα secretion (Lande et al., 2007).
If IFNα is essential for the pathogenesis of psoriasis, its block-
ade should reduce psoriatic symptoms. Indeed, using blocking
anti-IFNα antibodies prevented the development of psoriasis in
a xenograft model in mice (Nestle et al., 2005). In addition to
IFNα blockade other attempts to reestablish DCreg in psoriasis
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have been suggested. An interesting strategy to induce DCreg
was recently reported by stimulating DCs with the neuropep-
tide α-melanocyte-stimulating hormone (α-MSH). α-MSH stim-
ulated DCs downregulated the costimulatory molecules CD80
and CD86, upregulated the two coinhibitory molecules PD-L1
and PD-L2, as well as CD205 and secreted high amounts of
IL-10. These DCreg subsequently induced CD4+CD25+Foxp3+
Treg. Mutation experiments of the MC-1R gene showed that
the induction of DCreg was mediated by the binding of α-MSH
to the MC-1R and that this effect could ameliorate psoriasis
in vitro as well as in vivo (Auriemma et al., 2012). Another
approach to induce DCreg was based on vitamin D. An acti-
vated form of vitamin D, namely 1,25-dihydroxyvitamin D3
has been described to inhibit the differentiation and matura-
tion of DCs by its influence on RNA Polymerase II-mediated
transcription of response genes (Penna and Adorini, 2000).
Downregulation of activation-associated molecules such as CD1a
was associated with diminished IL-12 secretion, and upregu-
lation of IL-10 reprogramed DCs toward regulatory functions
thereby gaining the capacity to induce Treg cells (Piemonti et al.,
2000).
MYELOID CELLS ARE INVOLVED IN CHRONIC INFLAMMATION IN
OBESITY
The observation that increased adipose tissue in obesity is asso-
ciated with the influx of immune cells, mainly myeloid cells
has been made less than 10 years ago (Wellen and Hotamisligil,
2003; Chawla et al., 2011). Obesity is associated with Type 2
Diabetes (T2D), insulin resistance, arteriosclerosis, other cardio-
vascular diseases and even increased cancer risk (Lumeng and
Saltiel, 2011). Elevated levels of free fatty acids (FFAs) and pro-
inflammatory cytokines are hallmarks of the systemic low-grade
inflammation persisting in obese individuals (Roytblat et al.,
2000; Hansen et al., 2010). In mouse models massive infiltration
of immune cells into adipose tissue has been described suggest-
ing to promote high-fat died induced adipose tissue inflammation
(Duffaut et al., 2009; Strissel et al., 2010). While macrophages
clearly play amajor role during this chronic inflammation the role
of DCs in the inflammatory cross-talk of adipocytes and immune
cells is not yet clear (Table 1). The impact of dietary fatty acids on
the presence of DCs in adipose tissue adjacent to and remote from
lymph nodes has been investigated under conditions of chronic
mild inflammation induced by low doses of LPS in rats (Mattacks
et al., 2004). Chow containing fish oil which is rich in unsatu-
rated fatty acids (USFAs) is considered to reduce inflammatory
effects while diets enriched for oils containing saturated fatty acid
(SFAs) were associated with an increase of DCs in perinodal adi-
pose tissue (Mattacks et al., 2004). So far, little is known about
the role of elevated levels of FFAs on DC function. However,
one could speculate that—similar to macrophages—FFAs will
shape the functional program of DCs. Using fluorescently labeled
palmitic acid, it was recently demonstrated that DCs can uptake
fatty acids (Herber et al., 2010). Interestingly, little is known about
the accumulation and storage of FFAs in DCs and what role lipid
droplets might play in DCs. Increased levels of fatty acids have
an impact on antigen processing and presentation. Splenic DCs
derived from mice with non-alcoholic fat liver disease (NAFLD),
an obesity associated disease, were found to show an impaired
processing and presentation of HBsAg in the presence of the sat-
urated fatty acid palmitic acid, but not the unsaturated fatty acid
oleic acid (Miyake et al., 2010). Similarly, human blood-derived
DCs challenged with antigen demonstrated reduced antigen pre-
sentation in vitro, lower induction of T cell proliferation and
also an induction of the two pro-inflammatory cytokines IL-1β
and TNFα in the presence of palmitic acid but not oleic acid
(Miyake et al., 2010). Due to the complexity of FFAs concern-
ing saturation, length and isomer structure, it is very likely that
mixture of FFAs results in similarly complex immune responses
due to differential signal integration. For most FFAs the impact
on DC function is not yet understood. One possible receptor
for fatty acids is the scavenger receptor CD36 on DCs and var-
ious other cells (Silverstein and Febbraio, 2009). But also PRR
are involved in the detection of some FFAs. For example, the
satured fatty acid lauric acid is recognized via TLR4, one of the
major receptors for PPRs on DCs. Recognition of lauric acid via
TLR4 was found to upregulate costimulatory molecules CD40,
CD80, CD86, MHCII, and to enhance secretion of IL-12 subse-
quently triggering T cell activation (Weatherill et al., 2005). The
opposite effect was shown for DCs stimulated with the omega-
3 unsaturated fatty acid docosahexaenoic acid. This fatty acid
inhibited LPS-induced upregulation of CD40, CD80, and CD86
as well as MHC class II molecules and prevented T cell activa-
tion. Due to these immunoinhibitory effects of unsaturated fatty
acids, they might be useful as therapeutics in chronic inflam-
matory diseases, including obesity, cardiovascular disease, Bowel
disease, Crohn’s disease, or chronic obstructive pulmonary dis-
ease (Blok et al., 1996; Caughey et al., 1996; Calder, 1997; De
Batlle et al., 2011; Bassaganya-Riera et al., 2012; Huang et al.,
2012). A cis-9, trans-11 isomer of conjugated linoleic acid is a
poly-unsaturated fatty acid naturally occurring in meat, milk,
and other nutrients. It has been shown to induce the expres-
sion of the anti-inflammatory cytokine IL-10 in murine bone-
marrow derived DCs in an ERK dependent fashion (Loscher
et al., 2005). As negative feedback loop IL-10 inhibited NFκB
leading to suppression of its downstream target IL-12 which
might contribute to its immunosuppressive properties on TH1
cell activation (Loscher et al., 2005). Besides TLR4 also peroxi-
some proliferation-activator receptor-gamma (PPARγ) can affect
thematuration status of DCs (Chinetti et al., 2000; Nencioni et al.,
2002). Upregulation of PPARγ was observed in docosahexaenoic
acid or eicosapentaenoic acid stimulated bone marrow derived
DCs. These cells showed reduced IL-12 secretion, reduced expres-
sion of costimulatory molecules, and reduced NFκB activity, but
enhanced expression of IL-10R and its ligand IL-10 (Draper
et al., 2011). Despite an increased physical interaction and cellular
colocalization of NFκB and PPARγ the same study showed that
the anti-inflammatory effect of the two tested omega-3 USFAs
was not abolished by the inhibition of PPARγ with a chemical
inhibitor compound. These results lead to the conclusion, that
PPARγ might be an intracellular receptor for unsaturated fatty
acids but cannot be singularly made responsible for the inflam-
matory effects of polyunsaturated fatty acids. Finally, it should
be mentioned that resolvins and lipoxins, metabolites of docosa-
hexaenoic acid or eicosapentaenoic acid, have anti-inflammatory
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functions and are involved in downregulation of IL-12 secretion
in DCs via downregulation of the chemokine receptor 5 (CCR5)
(Aliberti et al., 2002).
Beneficial usage of omega-3 unsaturated fatty acids has been
shown in clinical trials to improve plasma triglyceride levels
and insulin activity in T2D patients (Hendrich, 2010). T2D
is often associated with obesity and characterized by elevated
plasma concentrations of the pro-inflammatory cytokines TNFα
and granulocyte-macrophage colony-stimulating factor driving
chronic low grade inflammation systemically (Surendar et al.,
2012). These two pro-inflammatory mediators contribute to
the activation of circulating CD85+CD123+ pDCs and CD85+
CD33+ CD123dim mDCs yet the overall number of DCs is
reduced in T2D making diabetic patients prone to infections
(Seifarth et al., 2008; Blank et al., 2010). Interestingly, DCs seem
to be reprogrammed once concomitant health problems such as
arteriosclerosis are acquired. In T2D patients with atheroscle-
rotic complications circulatingmonocytes andDCs show reduced
production of pro-inflammatory mediators like TNFα which is
associated with impaired T cell activation (Corrales et al., 2007).
Taken together, DCs like macrophages are involved in chronic
low-grade inflammation observed in obesity. Elevated levels of
free fatty acids, a hallmark of obesity, have substantial influences
on DCs with saturated fatty acids inducing pro-inflammatory
immune mediators. On the other hand, unsaturated fatty acids
seem to suppress inflammation and are currently investigated as
an attractive therapeutic option in obesity. Therefore, unsaturated
fatty acids constitute yet another mechanism capable of inducing
regulatory programs in DCs.
REGULATORY DCs ARE INDUCED DURING CHRONIC
INFECTIONS
In general, the immune system is equipped to resolve most
acute infections by completely removing invading pathogens.
However, some pathogens have evolved strategies to escape a
resolving immune response and as a consequence induce chroni-
fication of the infection. Chronic infections are also characterized
by a deviated immune response often resulting in a prevalence
of immunoregulatory mechanisms including regulatory cells. In
fact, increasing evidence exists suggesting that DCreg also play a
role in chronic infections. In some situations such as the devel-
opment of chronic granulomatous infections, the development
of regulatory mechanisms actually might be the last resort of the
host to keep the invading pathogens in check. Using a few exam-
ples, we illustrate the evidence for DCreg in chronic infections.
DEVIATION OF DC FUNCTION DURING VIRAL INFECTIONS
Under normal conditions, RNA and DNA viruses activate DCs
e.g., via the PPRs TLR7 or TLR9 resulting in enhancement of
IFNα production bymatured DCs. In some viral infections lack of
viral clearance is—at least in part—due to lack of an effective DC
activation and maturation (Table 1). For example although hep-
atitis C virus (HCV) is recognized by DCs via binding of the HCV
envelope 2 protein to surface receptors such as SRBI, DC-SIGN,
CD81 or TLR receptors other viral proteins inhibit important
steps of DC maturation, prevent IL-12 induction and subse-
quently reduce their capacity to induce T cell activation (Sarobe
et al., 2003). During monocyte differentiation HCV inhibits the
expression of CD1a, CD1b, and DC-SIGN, but induces these
DCs to secret IL-10 preventing T cell expansion (Tu et al., 2012).
Attempts to decipher the molecular mechanism of the immune
suppressive pathways activated by HCV revealed that after expo-
sure of pDCs to HCV-infected hepatoma cells they activated IRF7
but not the central pro-inflammatory transcription factor NFκB.
These finding might explain, why pDCs in HCV infection secrete
IFNα but are not able to produce IL-6 or TNFα (Dental et al.,
2012). In mice, the function of DCs was recovered when DCs
were pulsed ex vivo with the viral protein NS3 and matured in
the presence of CpG (Yu et al., 2006). Unlike HCV infection,
the capability to secrete IL-12 is not impaired in herpes sim-
plex virus type 1 (HSV1) infected DCs. In an initial report, DCs
infected with HSV1 were reported to show many phenotypical
features of matured DCs except for a loss of CD83 and reduced T
cell stimulating activity (Kruse et al., 2000). A more recent study
however demonstrated in a murine model that the HSV1 latency-
associated transcript (LAT) is involved in the downregulation
of costimulatory molecules and pro-inflammatory cytokines like
IL-6, IL-12, and TNFα (Chentoufi et al., 2012). Impaired DC
function was also suggested to contribute to the reduced function
of HSV-specific CD8+ T cells (Chentoufi et al., 2012). Moreover,
LAT can function like endogenous cFLIP inhibiting caspase-
8 mediated apoptosis in HSV-infected DCs thereby ensuring
spreading and replication of the virus (Kather et al., 2010). Yet
other mechanisms of immune deviation operative in DCs have
been suggested for human immunodeficiency virus (HIV) infec-
tion. In the early phase of primary HIV infection, numbers of
CD11c+ mDCs as well as CD123+ pDC are decreased resulting
in a lack of anti-viral IFNα expression (Pacanowski et al., 2001).
Infected DCs display a rather immature phenotype because they
do not really upregulate typical activation markers like MHC
class II, CD83, CD80, CD86, or CCR7 (Smed-Sorensen et al.,
2004; Martinson et al., 2007). Their functional potential is con-
troversially discussed. Although the number of circulating DCs
is declinedin HIV patients, the remaining DCs seem to keep
a certain immune activating potential as exemplified by CD86
upregulation after stimulation with CD40L. Also these DC secrete
TNFα, IL-1β, and IL-10 but do not secrete IL-12 p70 or IFNα
(Smed-Sorensen et al., 2004; Martinson et al., 2007). The induc-
tion of IFN regulatory factor 1 (IRF-1) by HIV infection of DCs
was shown to induce IFN-stimulated genes without the expres-
sion of type I and II interferons thereby ensuring the replication of
the HIV in mDCs (Harman et al., 2011). In fact, the loss of IFNα
production of HIV infected pDCs was postulated to contribute to
progression of the disease (Tilton et al., 2008). Furthermore, HIV
infected DCs are resistant to NK cell mediated cell death. Melki
and coworkers showed an upregulation of the anti-apoptotic
molecules c-FLIP and c-IAP2 in these DCs rendering them resis-
tant to TRAIL-induced cell death via interaction between TRAIL
on the cell surface of NK cells and its receptor DR4 on DCs (Melki
et al., 2010).
These are only few examples, demonstrating that the induc-
tion of DCs with regulatory rather than stimulatory functions is
a major theme of many viruses capable of escaping an efficient
immune response thereby inducing viral persistence.
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DCreg ARE ESSENTIAL PLAYERS IN CHRONIC GRANULOMATOUS
LISTERIOSIS
Myeloid cells with regulatory function have also been implicated
in the formation and maintenance of granulomatous structures
that are supposed to enclose pathogens thereby preventing their
dissemination (Table 1). While macrophages play the major role
inmost granulomatous diseases chronic granulomatous listeriosis
is characterized by large quantities of DCs within the cellu-
lar ring wall of the granuloma (Popov et al., 2006). Listeriosis
is caused by the gram positive bacteria Listeria monocytogenes
(L.m.). In the immunocompetent host, clinical manifestation
is characterized by a self-limiting gastroenteritis. However, in
immunocompromised individuals, but also elderly people and
newborns L.m. can cause chronical meningoencephalitis and sep-
ticemia (Swaminathan and Gerner-Smidt, 2007; Allerberger and
Wagner, 2010; Mook et al., 2011). Moreover, advanced stages
of chronic disease are characterized by granulomas in lymph
node tissue (Gray and Killinger, 1966). Granulomas are organized
immune cell aggregates that form in response to persistent stim-
uli of infectious or non-infectious nature (Ramakrishnan, 2012).
Recently, our group discovered that CD11c+ S100+ IDO+ mDCs
are predominant constituent elements in the outer wall of listeria
granuloma (Popov et al., 2006, 2008; Von Bergwelt-Baildon et al.,
2006). Transcriptome profiling of L.m. infected mDCs revealed
that infection of mDCs leads to the upregulation of numerous
effector molecules including TNFα, IFNγ, IL-10, COX-2, IDO,
and CD25 that act together in a regulatory fashion (Popov et al.,
2008). Supernatants derived from mDCs infected by L.m. sup-
pressed T cell proliferation via a mechanism that involves IDO
activity, (Popov et al., 2008 and Schultze, unpublished data).
Furthermore, IDO+ mDCs were also capable to keep L.m. in
check, suggesting that IDO-competent mDC possess microbi-
cidal activity (Popov et al., 2006, 2008; Von Bergwelt-Baildon
et al., 2006) and Nino-Castro, unpublished results). These regu-
latory DC seem to have at least three critical roles during chronic
listeriosis. First, they are involved in the formation and main-
tenance of the granulomatous structure, second, they keep the
pathogen in check, and third, they suppress T cell effector func-
tion that could destroy the granulomatous structure. Therefore,
these DCreg are essential for the formation and maintenance of
this immune priviledged site (Mellor and Munn, 2004) at the
same time acting as a barrier that controls bacterial growth and
dissemination via an IDO mediated mechanism.
DCreg ARE IMPORTANT CELLS IN NUMEROUS PARASITICAL
INFECTIONS
Despite their phylogenetic diversity, parasitic protozoans and
helminthes have the ability in common to produce long lasting
chronic infections (Peters and Sacks, 2006). Understanding how
parasitical infections can progress toward chronicification poses
a challenge due to the complex host pathogen interactions that
depend on the immunological status of the host, but also on the
genetic background of both pathogen and host. Some evidence
suggests a role for DCs with regulatory function during infection
with parasites.
Species of the genus Leishmania are the causing agents of leish-
maniases, a group of illnesses of the oral and respiratory mucosae,
the skin, and the reticuloendothelium (Reithinger et al., 2007).
The cutaneous form is the most common one and is also known
to evolve into a chronic disease. Recently, it has been reported in a
murine model, that a subset of Langerin+ Langerhans cells might
favor the recruitment of Treg cells to the site of infection resulting
in aggravated disease. This DC subset was able to promote Treg
expansion in vitro (Kautz-Neu et al., 2011). Moreover, it has been
reported that mice infected with Leishmania major upregulate
IDO expression in lymph node pDCs. IDO+ pDCs suppressed
T cell activation and proliferation in vitro. Furthermore, the inhi-
bition of the IDO enzymatic activity resulted in an improvement
of the immune response toward L. major manifested by a reduc-
tion in lesion size and parasitical burden (Makala et al., 2011).
Although IDO has a well-known microbicidal role by limiting
pathogen spread via Trp depletion, the evidence in Leishmania
infection suggest that in this context IDO+ pDCs are deleterious
to the host, due to their capacity to attenuate adaptive immune
responses. Finally, Nguyen and coworkers reported that infection
of murine bone marrow stromal cells by Leishmania donovani
enhanced their capacity to attract hematopoietic progenitor cells.
L. donovani infected stromal cells were able to support the devel-
opment DCs from hematopoietic progenitor cells. Moreover, this
DC subset acquired regulatory properties being able to suppress
CD4+ T cell proliferation in vitro (Nguyen Hoang et al., 2010). In
summary, there is sufficient evidence that different DC popula-
tions can acquire regulatory functions in response to Leishmania
infection, however their exact role during chronification of the
disease is not yet fully understood.
Another example for the involvement of DCreg in parasite
infections is Chagas disease caused by the parasite Trypanosoma
cruzi. In most patients with Chagas disease an immune response
develops, the parasitemia wanes, and signs and symptoms resolve
completely within a few months. However, around 30% of the
patients will progress toward a chronic disease (Hemmige et al.,
2012). The mechanisms that control the progression of the dis-
ease into a chronic phase are widely unknown (Sathler-Avelar
et al., 2009). Recently, it has been reported that coculture of DCs
with T. cruzi trypommastigotes in vitro leads to production of IL-
10 and TGFβ by DCs. Furthermore, these cells suppressed T cell
proliferation in vitro (Poncini et al., 2008), which indicates that
T. cruzi might induce DCs with regulatory functions to evade
the host immune system. However, to our knowledge there is no
evidence yet supporting the role of DCreg as promoters of tol-
erance toward T. cruzi in infected hosts in vivo. Therefore, the
potential role of DCreg in the overall immune response against
this pathogen remains unclear. Nematode infections are known to
promote local immunosuppression in the host, allowing the par-
asite to achieve a long term survival, which is usually associated
with a local chronic infection (Taylor et al., 2005). Recently, Li and
coworkers described a naturally occurring DC subset with reg-
ulatory activity in the murine infection model of Heligmosoides
poligyrus. These CD11clow CD45mid DCreg expanded rapidly after
H. poligyrus infection and promoted Treg differentiation in vitro
(Li et al., 2011).
Taken together, chronification of infectious diseases is very
often accompanied by the induction of DCs with regulatory func-
tions. Reprogramming these APC away from immunostimulatory
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functions seems to be a central theme during the chronifica-
tion process. However, more work is required to really under-
stand the mechanisms that lead to the observed reprogramming
of DCs.
SUMMARY AND CONCLUSIONS
During the last two decades immunostimulatory functions of
DCs were the major focus of DC research (Steinman, 2007) con-
solidating that these extraordinary cells are the main contributors
for immune activation. However, during the last years accumulat-
ing evidence strongly suggests that DCs are much more versatile
in their functions allowing them to regulate (DCreg) or even halt
immune responses e.g., by inducing tolerance (tolerogenic DC).
DCreg are implicated in terminating inflammatory responses
under physiological conditions yet regulatory DC functions also
seem to be hijacked by pathologic conditions as different as
cancer or chronic infection. While several of the molecules asso-
ciated with regulatory DC function (IL-10, TGFβ, IDO, PGE2,
and CD25) have been elucidated and observed in numerous can-
cer entities and chronic infections, the molecular mechanisms
reprogramming DC to become DCreg are still poorly understood.
Many previous studies are rather descriptive and many findings
in murine and rodent models often could not be translated
to the human, leaving researchers confronted with the prob-
lem to investigate molecular mechanisms of DCreg involvement
in human specimens. However, the availability of sequencing-
based genomic technologies assessing networks of epigenetic,
transcriptional, and translational regulation on a genome-wide
scale and in an unprecedented resolution makes research into
human DCreg biology a very promising endeavor. We envision
that the integration of such data will allow us in the future
to better understand how exogenous signals are integrated in
DCs to foster a regulatory rather than an immunostimulatory
program. Moreover, signal integration is not only restricted to
classical pro- and anti-inflammatory mediators but is further
altered by a myriad of soluble and cell-contact mediated sig-
nals as exemplified here for metabolites like kynurenines or
unsaturated fatty acids. Moreover, understanding DCreg biol-
ogy will also guide the development of better DC-based vac-
cines, e.g., as cancer immunotherapy. Unraveling differential and
context-dependent signal integration by DCs during activation
will also lead to the discovery of genes that could be targeted for
immunomodulation.
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